{"id":"mepolizumab-injection-nucala","safety":{"commonSideEffects":[{"rate":"7–8","effect":"Headache"},{"rate":"5–7","effect":"Injection site reaction"},{"rate":"4–6","effect":"Back pain"},{"rate":"3–5","effect":"Fatigue"},{"rate":"5–10","effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-5 is a key cytokine that promotes eosinophil development, recruitment, and survival. By blocking IL-5, mepolizumab reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in eosinophil-driven diseases such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).","oneSentence":"Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the blood and tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:23.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe eosinophilic asthma"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"},{"name":"Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anti-IL5 treatment"],"phase":"marketed","status":"active","brandName":"Mepolizumab Injection [Nucala]","genericName":"Mepolizumab Injection [Nucala]","companyName":"KU Leuven","companyId":"ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the blood and tissues. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}